Open in Screener

MBX

MBX Biosciences Inc

Oct 03 • 04:00PM ET

16.69

-0.06 -0.36 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM IWN SCHA VXF VTWO FESM IWC SBIO BBC

Index	RUT	P/E	-	EPS (ttm)	-2.31	Insider Own	51.79%	Shs Outstand	33.59M	Perf Week	-4.68%
Market Cap	746.30M	Forward P/E	-	EPS next Y	-2.78	Insider Trans	3.00%	Shs Float	20.67M	Perf Month	29.18%
Enterprise Value	522.06M	PEG	-	EPS next Q	-0.70	Inst Own	42.94%	Short Float	20.45%	Perf Quarter	29.58%
Income	-77.02M	P/S	-	EPS this Y	53.49%	Inst Trans	2.76%	Short Ratio	3.91	Perf Half Y	162.01%
Sales	0.00M	P/B	2.56	EPS next Y	-2.64%	ROA	-52.32%	Short Interest	4.23M	Perf YTD	-9.44%
Book/sh	6.53	P/C	3.32	EPS next 5Y	17.46%	ROE	-56.28%	52W High	27.50 -39.31%	Perf Year	-30.63%
Cash/sh	5.03	P/FCF	-	EPS past 3/5Y	-53.83% -	ROIC	-35.05%	52W Low	4.81 247.21%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.51% 12.00%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.97	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.50	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.30	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	19.50	EPS Q/Q	-22.16%	SMA20	17.27%	Beta	1.07	Target Price	60.29
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	20.64%	Rel Volume	1.55	Prev Close	16.75
Employees	43	LT Debt/Eq	0.00	Earnings	Aug 07 BMO	SMA200	39.51%	Avg Volume	1.08M	Price	16.69
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	21.06% -	Trades		Volume	1,678,042	Change	-0.36%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-25	Resumed	Jefferies	Buy	$36
Aug-05-25	Initiated	Mizuho	Outperform	$38
Jul-16-25	Initiated	Oppenheimer	Outperform	$38
Apr-10-25	Initiated	Citizens JMP	Mkt Outperform	$38
Oct-08-24	Initiated	Stifel	Buy	$40
Oct-08-24	Initiated	JP Morgan	Overweight	$30
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$44

Sep-29-25 08:00AM	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire)
Sep-24-25 09:15PM	MBX Biosciences Announces Pricing of Upsized Public Offering (GlobeNewswire) +6.01% -13.78%
Sep-23-25 09:55AM	Wall Street Analysts Think MBX Biosciences, Inc. (MBX) Could Surge 88.55%: Read This Before Placing a Bet (Zacks) -5.20%
06:45AM	MBX to advance hypoparathyroidism drug to Phase III trial (Clinical Trials Arena)
04:54AM	FDA clears under-the-skin Keytruda; MBX shares double on study data (BioPharma Dive)
04:14PM	Loading…
Sep-22-25 04:14PM	MBX Biosciences Announces Proposed Public Offering (GlobeNewswire) +100.00%
04:03PM	MBX Biosciences Stock Doubles On Promising New Thyroid Disease Treatment (Investor's Business Daily)
09:34AM	MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug Promise (Investor's Business Daily)
08:28AM	MBX Biosciences' Experimental Drug Shows Promise In Hypoparathyroidism Study (Benzinga)
07:00AM	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension (GlobeNewswire)
Sep-19-25 04:18PM	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 (GlobeNewswire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-04-25 08:00AM	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity (GlobeNewswire) -10.28%
Aug-20-25 12:13AM	MBX Biosciences Submits IND for Once-Monthly Obesity Drug (Insider Monkey)
Aug-07-25 08:00AM	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
09:37AM	Loading…
Aug-05-25 09:37AM	Block downgraded, Wayfair upgraded: Wall Street's top analyst calls (The Fly)
Jun-23-25 08:00AM	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development (GlobeNewswire)
Jun-16-25 08:00AM	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity (GlobeNewswire)
Jun-10-25 08:00AM	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions (GlobeNewswire)
May-20-25 08:00AM	MBX Biosciences to Participate in June Investor Conferences (GlobeNewswire)
May-15-25 07:16AM	Microbix Reports Results for Q2 Fiscal 2025 (GlobeNewswire)
May-13-25 07:00AM	Microbix & Aurevia Introduce Novel EQA Scheme (GlobeNewswire) -7.81%
May-12-25 08:00AM	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-08-25 07:00AM	Microbix Schedules Release of Results for Q2 Fiscal 2025 (GlobeNewswire) +8.13%
May-05-25 07:00AM	Microbix's Clot-Buster Drug Project Advances (GlobeNewswire)
Apr-22-25 08:00AM	MBX Biosciences to Participate in Citizens and RBC May Investor Conferences (GlobeNewswire) +13.09%
Apr-07-25 08:00AM	MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Mar-26-25 08:00AM	MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 08:00AM	MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-05-25 08:00AM	MBX Biosciences Announces Additions to Leadership Team (GlobeNewswire)
08:00AM	Loading…
Mar-03-25 08:00AM	MBX Biosciences Completes Enrollment in Phase 2 Avail Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism (GlobeNewswire) +5.62%
Feb-18-25 08:00AM	MBX Biosciences to Participate in March Investor Conferences (GlobeNewswire)
Jan-23-25 08:00AM	MBX Biosciences to Participate in Upcoming February Investor Conferences (GlobeNewswire) +8.11%
Jan-07-25 11:47AM	MBX Biosciences' Investigational Drug For Weight Loss Surgery-Related Low Blood Sugar Shows Encouraging Action (Benzinga) -10.32%
07:00AM	MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia (GlobeNewswire)
Dec-18-24 08:00AM	MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-02-24 08:00AM	MBX Biosciences Announces MBX 2109 Phase 1 Study Results Published in The Journal of Clinical Endocrinology and Metabolism (GlobeNewswire) -6.59%
Nov-18-24 08:00AM	MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia (GlobeNewswire) -6.76%
Nov-07-24 08:00AM	MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-28-24 08:00AM	MBX Biosciences to Participate in Upcoming November Investor Conferences (GlobeNewswire) -6.50%
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks)
Sep-30-24 08:00AM	MBX Biosciences Presents MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting (GlobeNewswire) +8.48%
Sep-23-24 07:05PM	Deep Track Capital, LP's Strategic Acquisition in MBX Biosciences Inc (GuruFocus.com)
Sep-18-24 03:19AM	OrbiMed Advisors LLC Acquires New Stake in MBX Biosciences Inc (GuruFocus.com)
Sep-16-24 04:05PM	MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -8.46%
Sep-12-24 07:11PM	MBX Biosciences Announces Pricing of Initial Public Offering (GlobeNewswire)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heron Patrick J	Director	Sep 26 '25	Buy	18.00	666,666	11,999,988	5,219,440	Sep 30 04:59 PM
Pescovitz Ora H.	Director	Apr 08 '25	Buy	5.89	7,693	45,312	24,329	Apr 10 08:39 AM
GORDON CARL L	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:56 PM
GORDON CARL L	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:56 PM
ORBIMED ADVISORS LLC	Director	Feb 18 '25	Buy	10.84	143,170	1,551,963	3,255,000	Feb 19 05:52 PM
ORBIMED ADVISORS LLC	Director	Feb 14 '25	Buy	9.87	47,502	468,793	3,205,930	Feb 19 05:52 PM
Hawryluk P. Kent	President & CEO	Feb 04 '25	Buy	10.69	50,000	534,500	448,277	Feb 05 04:17 PM

Open in Screener

ARQT

Arcutis Biotherapeutics Inc

Oct 03 • 04:00PM ET

19.92

-1.33 -6.26 %

Healthcare • Biotechnology • USA • NASD

ARQT Arcutis Biotherapeutics Inc daily Stock Chart

Peers: BMRN ANAB RCUS BCRX TVRD CNTA DERM VERU SLNO KZIA

| Held by: IWM VTI XBI IWO VXF IBB SCHA VTWO VHT PINK

Index	RUT	P/E	-	EPS (ttm)	-0.74	Insider Own	12.67%	Shs Outstand	119.80M	Perf Week	13.38%
Market Cap	2.39B	Forward P/E	113.83	EPS next Y	0.17	Insider Trans	-1.38%	Shs Float	104.74M	Perf Month	22.89%
Enterprise Value	2.31B	PEG	-	EPS next Q	-0.09	Inst Own	98.85%	Short Float	15.32%	Perf Quarter	48.77%
Income	-93.27M	P/S	9.07	EPS this Y	61.21%	Inst Trans	0.63%	Short Ratio	9.23	Perf Half Y	23.27%
Sales	263.46M	P/B	17.17	EPS next Y	138.89%	ROA	-23.40%	Short Interest	16.05M	Perf YTD	43.00%
Book/sh	1.16	P/C	12.50	EPS next 5Y	-	ROE	-57.33%	52W High	21.29 -6.43%	Perf Year	108.59%
Cash/sh	1.59	P/FCF	-	EPS past 3/5Y	34.80% -0.98%	ROIC	-37.59%	52W Low	8.03 148.07%	Perf 3Y	5.06%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.10%	Volatility	7.21% 4.90%	Perf 5Y	-25.56%
Dividend TTM	-	EV/Sales	8.76	EPS Y/Y TTM	65.91%	Oper. Margin	-32.58%	ATR (14)	0.95	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.04	Sales Y/Y TTM	99.50%	Profit Margin	-35.40%	RSI (14)	64.99	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	3.20	EPS Q/Q	70.48%	SMA20	11.00%	Beta	1.94	Target Price	22.75
Payout	-	Debt/Eq	0.79	Sales Q/Q	164.13%	SMA50	21.23%	Rel Volume	1.53	Prev Close	21.25
Employees	342	LT Debt/Eq	0.79	Earnings	Oct 28 BMO	SMA200	35.38%	Avg Volume	1.74M	Price	19.92
IPO	Jan 31, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.59% 10.61%	Trades		Volume	2,660,110	Change	-6.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-25-25	Initiated	Goldman	Neutral	$18
Dec-30-24	Initiated	H.C. Wainwright	Buy	$19
Aug-28-24	Initiated	Jefferies	Buy	$15
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Oct-03-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.26%
Oct-01-25 09:15AM	Arcutis Biotherapeutics, Inc. (ARQT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-29-25 04:00PM	Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 (GlobeNewswire) +5.98%
11:38AM	Biotech Leader Arcutis Is Breaking Out, Up Nearly 36% in 2025 (Investor's Business Daily)
09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
12:00PM	Loading…
Sep-25-25 12:00PM	Here's Why Arcutis Biotherapeutics, Inc. (ARQT) is a Great Momentum Stock to Buy (Zacks)
Sep-17-25 04:00AM	Arcutis To Present Multiple New ZORYVE (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-16-25 09:00AM	Allure Magazine Honors Arcutis' ZORYVE (roflumilast) with Prestigious Best of Beauty Breakthrough Award (GlobeNewswire)
Sep-12-25 09:40AM	Are Medical Stocks Lagging AxoGen (AXGN) This Year? (Zacks)
Sep-11-25 11:17AM	Arcutis Biotherapeutics, Inc. (ARQT) Eyes Pediatric Expansion for ZORYVE Cream (Insider Monkey)
Sep-10-25 12:20AM	Arcutis Biotherapeutics Submits Supplemental New Drug Application to FDA For ZORYVE (Insider Monkey)
Sep-05-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.80%
Sep-03-25 11:43AM	Arcutis Submits Supplemental New Drug Application for ZORYVE (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 (GlobeNewswire)
Sep-01-25 09:55AM	Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
06:33PM	Loading…
Aug-25-25 06:33PM	3 Biotech Catalysts Present Major Opportunity (MarketBeat)
Aug-19-25 04:00PM	Arcutis to Present at Upcoming Investor Conferences (GlobeNewswire) -5.79%
Aug-15-25 10:06AM	This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine (Investor's Business Daily) +5.69%
Aug-14-25 09:55AM	Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know (Zacks)
Aug-11-25 09:40AM	Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year? (Zacks)
Aug-08-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -8.07%
04:00PM	Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-25 09:49AM	Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com) +5.54%
Jul-30-25 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-23-25 04:00PM	Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (GlobeNewswire)
Jul-17-25 12:28PM	Arcutis Stock Awaits Next Move In A Base; Its Skin Drug Sales Grew 196% (Investor's Business Daily)
Jul-10-25 02:26PM	Arcutis Biotherapeutics Stock Scores RS Rating Upgrade (Investor's Business Daily) +7.38%
Jul-09-25 12:55AM	Arcutis' ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis (Insider Monkey)
Jul-03-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Jun-26-25 08:00AM	Arcutis' ZORYVE (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis (GlobeNewswire)
Jun-15-25 05:43AM	Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials (Insider Monkey)
Jun-11-25 07:03AM	First child enrolled in Arcutis Phase II trial of cream for atopic dermatitis (Clinical Trials Arena)
Jun-10-25 08:00AM	Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis (GlobeNewswire)
Jun-06-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.37%
08:00AM	Arcutis to Present New Long-Term Results of ZORYVE (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference (GlobeNewswire)
May-29-25 04:00PM	Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 02:12PM	Arcutis' ZORYVE (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older (GlobeNewswire)
May-15-25 09:29AM	New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice (GlobeNewswire)
May-08-25 11:26AM	Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements (TipRanks)
May-07-25 11:47AM	Q1 2025 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
11:18AM	Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE (roflumilast) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology (GlobeNewswire)
03:21AM	Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-06-25 11:00PM	Arcutis Biotherapeutics, Inc. (ARQT) Q1 2025 Earnings Call Transcript (Seeking Alpha) -7.07%
05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-05-25 09:43AM	What To Expect From Arcutis Biotherapeutics Inc (ARQT) Q1 2025 Earnings (GuruFocus.com)
May-02-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-25 08:15AM	Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-29-25 10:01AM	Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-24-25 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-19-25 01:41AM	Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets (Seeking Alpha)
Apr-17-25 08:00AM	Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025 (GlobeNewswire)
Apr-10-25 04:30PM	Arcutis Announces Chief Financial Officer Transition (GlobeNewswire) -7.76% -6.32%
Apr-04-25 11:10PM	Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) (Seeking Alpha) -8.85%
04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-03-25 10:01AM	Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last? (Zacks)
04:47AM	Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday? (Insider Monkey)
Apr-02-25 01:16PM	Arcutis and Padagis Agree to Stay Patent Lawsuit (GlobeNewswire) +10.81%
Mar-28-25 04:15PM	Why IBD 50's Arcutis Is Outplaying The Biotech Tape And Just Reentered Its Buy Zone (Investor's Business Daily)
09:55AM	How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85% (Zacks)
09:40AM	Are Medical Stocks Lagging Cardinal Health (CAH) This Year? (Zacks)
Mar-27-25 08:00AM	Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-25 07:00AM	ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age (PR Newswire) +12.31%
Mar-12-25 09:40AM	Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year? (Zacks)
Mar-07-25 08:00AM	Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting (GlobeNewswire)
Mar-06-25 09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average (Zacks)
Mar-05-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.30%
09:55AM	Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? (Zacks)
Feb-28-25 09:00AM	Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting (GlobeNewswire) +6.95%
Feb-26-25 08:00AM	U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis (GlobeNewswire) +8.36%
02:15AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-25-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:00PM	Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
01:33AM	Arcutis Biotherapeutics Inc (ARQT) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-25 08:00AM	Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology (GlobeNewswire)
Feb-18-25 04:35PM	Arcutis to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Feb-17-25 09:55AM	Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 51.64%: Read This Before Placing a Bet (Zacks)
Feb-13-25 10:18AM	Arcutis Biotherapeutics (ARQT) Surges 15.9%: Is This an Indication of Further Gains? (Zacks) -6.81%
Feb-11-25 09:55AM	Here's Why Arcutis Biotherapeutics (ARQT) Could be Great Choice for a Bottom Fisher (Zacks)
Feb-06-25 08:00AM	Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. (Investor's Business Daily) -5.77%
Feb-05-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-04-25 09:15AM	Odell Beckham Jr. and Arcutis Tackle Seborrheic Dermatitis in a 'Clear Win for Your Skin' (PR Newswire)
Jan-27-25 08:00AM	Arcutis to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-16-25 09:55AM	Wall Street Analysts Believe Arcutis Biotherapeutics (ARQT) Could Rally 37.43%: Here's is How to Trade (Zacks)
Jan-12-25 08:30AM	Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million (GlobeNewswire)
Jan-06-25 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
Dec-16-24 08:00AM	Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis (GlobeNewswire) +6.93%
Dec-06-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 08:00AM	Arcutis Announces Promotions on Executive Management Team (GlobeNewswire)
Nov-27-24 09:55AM	Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? (Zacks)
09:55AM	Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Nov-20-24 09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average (Zacks)
09:30AM	Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
Nov-19-24 09:55AM	Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now (Zacks) +7.00%
09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Nov-13-24 08:00AM	Arcutis' ZORYVE (roflumilast) Awarded Best Eczema Treatment by Glamour (GlobeNewswire)
Nov-11-24 09:55AM	Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? (Zacks)
Nov-07-24 02:23AM	Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... (GuruFocus.com) +7.66%

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Watanabe Todd	See Remarks	Oct 01 '25	Sale	19.33	24,261	469,074	867,179	Oct 03 05:02 PM
Watanabe Todd	See Remarks	Oct 02 '25	Sale	20.04	20,739	415,574	846,440	Oct 03 05:02 PM
Welgus Howard G.	Director	Oct 01 '25	Option Exercise	1.68	9,538	16,030	109,744	Oct 03 05:01 PM
Welgus Howard G.	Director	Oct 01 '25	Sale	18.92	10,000	189,227	99,744	Oct 03 05:01 PM
Todd Franklin Watanabe	Officer	Oct 02 '25	Proposed Sale	20.04	20,739	415,574		Oct 02 04:43 PM
Larry Todd Edwards	officer	Oct 02 '25	Proposed Sale	20.04	4,504	90,263		Oct 02 04:41 PM
Todd Franklin Watanabe	Officer	Oct 01 '25	Proposed Sale	19.33	24,261	469,074		Oct 01 05:35 PM
Howard Welgus	Director	Oct 01 '25	Proposed Sale	18.92	10,000	189,227		Oct 01 03:16 PM
Watanabe Todd	See Remarks	Sep 08 '25	Sale	17.54	9,625	168,799	891,944	Sep 10 06:21 PM
Watanabe Todd	See Remarks	Sep 09 '25	Sale	17.52	504	8,829	891,440	Sep 10 06:21 PM
Watanabe Todd	Officer	Sep 09 '25	Proposed Sale	17.52	504	8,829		Sep 09 03:17 PM
Matsuda Masaru	See Remarks	Sep 04 '25	Sale	16.16	36,130	583,716	161,234	Sep 08 05:14 PM
Watanabe Todd	Officer	Sep 08 '25	Proposed Sale	17.54	9,625	168,800		Sep 08 05:04 PM
Welgus Howard G.	Director	Sep 02 '25	Option Exercise	0.00	10,000	0	110,206	Sep 04 06:41 PM
Welgus Howard G.	Director	Sep 02 '25	Sale	15.64	10,000	156,383	100,206	Sep 04 06:41 PM
Matsuda Masaru	Officer	Sep 04 '25	Proposed Sale	16.16	36,130	583,716		Sep 04 04:21 PM
Welgus Howard G.	Director	Sep 02 '25	Proposed Sale	15.61	10,000	156,083		Sep 02 03:08 PM
Burnett Patrick	See Remarks	Aug 21 '25	Sale	15.57	2,438	37,969	104,811	Aug 21 09:32 PM
Burnett Patrick	See Remarks	Aug 19 '25	Sale	16.16	1,750	28,281	107,249	Aug 21 09:32 PM
Burnett Patrick	Officer	Aug 21 '25	Proposed Sale	15.57	2,438	37,969		Aug 21 05:27 PM
Burnett Patrick	Officer	Aug 19 '25	Proposed Sale	16.13	1,750	28,228		Aug 19 04:57 PM
Burnett Patrick	See Remarks	Aug 08 '25	Sale	14.03	3,847	53,988	108,999	Aug 12 05:04 PM
Topper David Joseph	Former Officer	Aug 08 '25	Proposed Sale	14.58	41,979	611,936		Aug 08 04:40 PM
Burnett Patrick	Officer	Aug 08 '25	Proposed Sale	14.03	3,847	53,989		Aug 08 04:10 PM
Topper David Joseph	Former Officer	Aug 06 '25	Proposed Sale	14.99	53,187	797,446		Aug 06 03:04 PM
Watanabe Todd	See Remarks	Aug 04 '25	Sale	14.33	11,547	165,429	901,569	Aug 05 06:29 PM
Burnett Patrick	See Remarks	Aug 04 '25	Sale	14.33	2,622	37,564	112,846	Aug 05 06:28 PM
Vairavan Latha	SVP Chief Financial Officer	Aug 04 '25	Sale	14.33	89	1,275	65,015	Aug 05 06:28 PM
Matsuda Masaru	See Remarks	Aug 04 '25	Sale	14.33	6,330	90,687	197,364	Aug 05 06:28 PM
Welgus Howard G.	Director	Aug 01 '25	Option Exercise	0.00	10,000	0	106,316	Aug 05 06:28 PM
Welgus Howard G.	Director	Aug 01 '25	Sale	14.30	10,000	142,982	100,206	Aug 05 06:28 PM
Watanabe Todd	Officer	Aug 04 '25	Proposed Sale	14.33	11,547	165,429		Aug 04 03:43 PM
Burnett Patrick	Officer	Aug 04 '25	Proposed Sale	14.33	2,622	37,564		Aug 04 03:42 PM
Matsuda Masaru	Officer	Aug 04 '25	Proposed Sale	14.33	6,330	90,687		Aug 04 03:40 PM
Vairavan Latha	Officer	Aug 04 '25	Proposed Sale	14.10	89	1,255		Aug 04 03:38 PM
Welgus Howard G.	Director	Aug 01 '25	Proposed Sale	14.30	10,000	142,982		Aug 01 04:20 PM
Burnett Patrick	See Remarks	Jul 10 '25	Option Exercise	0.00	23,000	0	138,468	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 14 '25	Option Exercise	0.00	5,750	0	121,218	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 10 '25	Sale	15.05	23,000	346,046	115,468	Jul 14 04:02 PM
Burnett Patrick	See Remarks	Jul 14 '25	Sale	15.07	5,750	86,654	115,468	Jul 14 04:02 PM
Burnett Patrick	Officer	Jul 14 '25	Proposed Sale	15.07	5,750	86,654		Jul 14 12:27 PM
Burnett Patrick	Officer	Jul 10 '25	Proposed Sale	15.05	23,000	346,047		Jul 10 03:55 PM
Welgus Howard G.	Director	Jul 01 '25	Sale	13.84	9,208	127,430	100,206	Jul 02 04:25 PM
Welgus Howard G.	Director	Jul 01 '25	Proposed Sale	13.84	9,208	127,431		Jul 01 10:12 AM
Welgus Howard G.	Director	Jun 18 '25	Sale	13.37	10,139	135,574	109,414	Jun 20 04:32 PM
Welgus Howard G.	Director	Jun 18 '25	Proposed Sale	13.37	10,139	135,573		Jun 18 02:09 PM
Heron Patrick J	Director	Jun 13 '25	Buy	13.08	2,646	34,610	27,448	Jun 17 05:45 PM
Heron Patrick J	Director	Jun 04 '25	Buy	13.32	1,890	25,177	24,424	Jun 06 08:44 AM
Heron Patrick J	Director	Jun 05 '25	Buy	13.41	378	5,069	24,802	Jun 06 08:44 AM
Matsuda Masaru	See Remarks	May 28 '25	Sale	13.78	1,800	24,807	202,599	May 29 08:25 PM
Matsuda Masaru	Officer	May 28 '25	Proposed Sale	13.78	1,800	24,807		May 28 03:47 PM
Heron Patrick J	Director	May 21 '25	Buy	13.66	2,520	34,423	20,014	May 23 04:04 PM
Heron Patrick J	Director	May 22 '25	Buy	13.65	2,520	34,398	22,534	May 23 04:04 PM
Edwards Larry Todd	See Remarks	May 19 '25	Sale	14.07	7,451	104,850	183,104	May 20 04:37 PM
Heron Patrick J	Director	May 15 '25	Buy	13.62	2,520	34,317	17,494	May 19 04:14 PM
Edwards Larry Todd	Officer	May 19 '25	Proposed Sale	14.07	7,451	104,850		May 19 03:54 PM
Heron Patrick J	Director	May 14 '25	Buy	13.76	6,300	86,691	14,974	May 15 04:18 PM
Heron Patrick J	Director	May 13 '25	Buy	13.76	2,374	32,661	8,674	May 15 04:18 PM
Heron Patrick J	Director	May 09 '25	Buy	13.60	6,300	85,691	6,300	May 13 04:11 PM
Burnett Patrick	See Remarks	May 08 '25	Sale	13.59	3,871	52,623	115,468	May 09 07:45 PM
Burnett Patrick	Officer	May 08 '25	Proposed Sale	13.59	3,871	52,623		May 08 02:54 PM
Matsuda Masaru	See Remarks	May 02 '25	Sale	15.20	5,030	76,453	204,399	May 05 05:20 PM
Watanabe Todd Franklin	See Remarks	May 02 '25	Sale	15.19	11,448	173,917	913,795	May 05 05:20 PM
Burnett Patrick	See Remarks	May 02 '25	Sale	15.19	2,597	39,442	119,339	May 05 05:20 PM
Welgus Howard G.	Director	May 01 '25	Sale	14.64	10,000	146,357	111,944	May 05 04:49 PM
Watanabe Todd Franklin	Officer	May 02 '25	Proposed Sale	15.19	11,448	173,917		May 02 04:24 PM
Burnett Patrick	Officer	May 02 '25	Proposed Sale	15.19	2,597	39,442		May 02 04:20 PM
Matsuda Masaru	Officer	May 02 '25	Proposed Sale	15.20	5,030	76,454		May 02 04:20 PM
Welgus Howard G.	Director	May 01 '25	Proposed Sale	14.64	10,000	146,357		May 01 04:21 PM
Welgus Howard G.	Director	Apr 01 '25	Sale	15.12	10,000	151,236	121,944	Apr 03 04:21 PM
Topper David Joseph	Chief Financial Officer	Apr 02 '25	Sale	15.80	9,600	151,698	182,774	Apr 03 04:21 PM
Topper David Joseph	Officer	Apr 02 '25	Proposed Sale	15.80	9,600	151,698		Apr 02 04:18 PM
Welgus Howard G.	Director	Apr 01 '25	Proposed Sale	15.12	10,000	151,236		Apr 01 04:07 PM
Watanabe Todd Franklin	See Remarks	Mar 25 '25	Sale	17.56	2,171	38,131	925,243	Mar 26 04:41 PM
Watanabe Todd Franklin	See Remarks	Mar 24 '25	Sale	17.52	1,500	26,282	927,414	Mar 26 04:41 PM
Watanabe Todd Franklin	Officer	Mar 25 '25	Proposed Sale	17.56	2,171	38,131		Mar 25 05:09 PM
Watanabe Todd Franklin	Officer	Mar 24 '25	Proposed Sale	17.52	1,500	26,282		Mar 24 04:20 PM
Watanabe Todd Franklin	See Remarks	Mar 17 '25	Sale	17.61	1,200	21,137	928,914	Mar 20 06:27 PM
Watanabe Todd Franklin	Officer	Mar 17 '25	Proposed Sale	17.61	1,200	21,137		Mar 20 05:03 PM
Burnett Patrick	See Remarks	Mar 13 '25	Option Exercise	0.00	5,008	0	126,944	Mar 17 04:51 PM
Burnett Patrick	See Remarks	Mar 14 '25	Option Exercise	0.00	12,242	0	134,178	Mar 17 04:51 PM
Burnett Patrick	See Remarks	Mar 13 '25	Sale	14.98	49,161	736,403	121,936	Mar 17 04:51 PM
Burnett Patrick	See Remarks	Mar 14 '25	Sale	15.04	12,242	184,107	121,936	Mar 17 04:51 PM
Burnett Patrick	Officer	Mar 04 '25	Proposed Sale	15.04	12,242	184,107		Mar 14 04:19 PM
Burnett Patrick	Officer	Mar 04 '25	Proposed Sale	14.98	49,161	736,403		Mar 13 05:10 PM
Burnett Patrick	See Remarks	Mar 03 '25	Sale	13.03	2,819	36,735	167,043	Mar 04 07:44 PM
Burnett Patrick	See Remarks	Mar 04 '25	Sale	13.28	954	12,673	166,089	Mar 04 07:44 PM
Watanabe Todd Franklin	See Remarks	Mar 03 '25	Sale	13.03	20,880	272,089	934,249	Mar 04 07:43 PM
Watanabe Todd Franklin	See Remarks	Mar 04 '25	Sale	13.28	4,135	54,930	930,114	Mar 04 07:43 PM
Welgus Howard G.	Director	Mar 03 '25	Sale	13.00	10,000	130,048	131,944	Mar 04 07:43 PM
Matsuda Masaru	See Remarks	Mar 03 '25	Sale	13.03	3,263	42,520	209,429	Mar 04 07:43 PM
Burnett Patrick	Officer	Mar 04 '25	Proposed Sale	13.28	954	12,673		Mar 04 04:47 PM
Watanabe Todd Franklin	Officer	Mar 04 '25	Proposed Sale	13.28	4,135	54,929		Mar 04 04:46 PM
Watanabe Todd Franklin	Officer	Mar 03 '25	Proposed Sale	13.03	20,880	272,089		Mar 03 05:39 PM
Matsuda Masaru	Officer	Mar 03 '25	Proposed Sale	13.03	3,263	42,520		Mar 03 05:38 PM
Burnett Patrick	Officer	Mar 03 '25	Proposed Sale	13.03	2,819	36,735		Mar 03 05:36 PM
Welgus Howard G.	Director	Mar 03 '25	Proposed Sale	13.00	10,000	130,048		Mar 03 04:50 PM
Matsuda Masaru	See Remarks	Feb 03 '25	Sale	12.70	8,338	105,893	178,692	Feb 04 08:01 PM
Watanabe Todd Franklin	See Remarks	Feb 03 '25	Sale	12.70	19,301	245,123	804,129	Feb 04 08:01 PM
Welgus Howard G.	Director	Feb 03 '25	Sale	12.71	10,000	127,100	141,944	Feb 04 08:00 PM

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Oct 03 • 04:00PM ET

72.95

+1.20 1.67 %

Healthcare • Biotechnology • USA • NASD

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Peers: VRTX GILD AKRO ENTA MDGL PTCT NBIX VKTX DVAX GLMD

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA VHT FYC

Index	RUT	P/E	-	EPS (ttm)	-1.21	Insider Own	19.12%	Shs Outstand	50.06M	Perf Week	0.26%
Market Cap	3.66B	Forward P/E	525.88	EPS next Y	0.14	Insider Trans	-1.33%	Shs Float	40.63M	Perf Month	-1.66%
Enterprise Value	3.68B	PEG	-	EPS next Q	-0.15	Inst Own	94.03%	Short Float	18.46%	Perf Quarter	44.54%
Income	-58.56M	P/S	8.54	EPS this Y	67.89%	Inst Trans	2.57%	Short Ratio	10.98	Perf Half Y	68.75%
Sales	429.16M	P/B	14.31	EPS next Y	123.35%	ROA	-8.45%	Short Interest	7.50M	Perf YTD	76.42%
Book/sh	5.10	P/C	12.03	EPS next 5Y	-	ROE	-24.19%	52W High	78.10 -6.59%	Perf Year	81.83%
Cash/sh	6.06	P/FCF	424.66	EPS past 3/5Y	12.58% 4.14%	ROIC	-10.24%	52W Low	36.88 97.80%	Perf 3Y	221.93%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	160.13% -	Gross Margin	78.93%	Volatility	3.16% 3.23%	Perf 5Y	291.36%
Dividend TTM	-	EV/Sales	8.57	EPS Y/Y TTM	48.34%	Oper. Margin	-13.30%	ATR (14)	2.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.97	Sales Y/Y TTM	62.33%	Profit Margin	-13.65%	RSI (14)	53.18	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	3.13	EPS Q/Q	77.40%	SMA20	-1.62%	Beta	0.76	Target Price	81.00
Payout	-	Debt/Eq	1.25	Sales Q/Q	64.09%	SMA50	7.07%	Rel Volume	0.72	Prev Close	71.75
Employees	322	LT Debt/Eq	1.24	Earnings	Aug 06 AMC	SMA200	41.20%	Avg Volume	682.92K	Price	72.95
IPO	Jul 18, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	63.22% 18.20%	Trades		Volume	490,360	Change	1.67%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	TD Cowen	Buy	$95
Aug-11-25	Resumed	Stifel	Buy	$89
May-19-25	Resumed	H.C. Wainwright	Buy	$73
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform

Show Previous Ratings

Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-10-25 06:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-08-25 08:00AM	Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study (Business Wire)
Aug-27-25 04:02PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-11-25 05:31PM	IBAT Inhibitors Market Witnesses Strong Growth During the Forecast Period (2025-2034) Owing to the Rising Demand for Rare Cholestatic Liver Disease Therapies \| DelveInsight (PR Newswire) +9.84%
09:33AM	Loading…
09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) +12.04%
Aug-06-25 05:55PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Jul-31-25 07:40AM	Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-30-25 04:01PM	Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 (Business Wire)
10:00AM	Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-17-25 10:02AM	Mirum Gains 35% in 3 Months: How Should You Play the Stock? (Zacks)
Jul-10-25 06:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-24-25 12:15PM	EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch (Zacks)
12:36PM	Loading…
Jun-17-25 12:36PM	Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up (Investor's Business Daily)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 11:30AM	Why Is Editas (EDIT) Up 40% Since Last Earnings Report? (Zacks)
Jun-10-25 08:40PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-25 11:31AM	Why Is Mirum Pharmaceuticals (MIRM) Down 1.3% Since Last Earnings Report? (Zacks)
Jun-03-25 11:41AM	FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch (Zacks)
May-19-25 08:30AM	Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer (Business Wire)
May-14-25 04:05PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Data from Mirums VANTAGE PBC Study Showcased at EASL (Business Wire)
May-08-25 12:13PM	Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised (Zacks) +9.75%
07:08AM	Q1 2025 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:29AM	Mirum Pharmaceuticals Inc (MIRM) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-07-25 09:17PM	Mirum pharmaceuticals raises 2025 revenue guidance to $435M-$450M driven by robust growth (Seeking Alpha)
09:17PM	Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Loading…
05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-06-25 05:05PM	Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -7.13%
May-05-25 10:00AM	Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
May-04-25 06:45PM	Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities (Seeking Alpha)
Apr-30-25 08:30AM	Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 (Business Wire)
Apr-28-25 08:30AM	Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses (Business Wire)
Apr-25-25 09:40AM	Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? (Zacks)
Apr-14-25 08:30AM	Mirums LIVMARLI Now FDA Approved in Tablet Formulation (Business Wire)
Apr-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.67%
Apr-03-25 09:34AM	Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? (Zacks)
Mar-28-25 11:30AM	Mirum Pharmaceuticals (MIRM) Down 1.9% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-27-25 08:30AM	LIVMARLI Now Approved in Japan for ALGS and PFIC (Business Wire)
Mar-24-25 05:17PM	Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call (SeekingAlpha)
12:24PM	Maintaining An 'Accumulate' Rating On Mirum Pharmaceuticals, Lots To Like (SeekingAlpha)
Mar-21-25 12:37PM	Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe (Zacks)
Mar-10-25 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 10:56AM	Q4 2024 Mirum Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.02%
02:22AM	Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Feb-26-25 05:15PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update (Business Wire)
11:48AM	Mirum Pharmaceuticals (MIRM): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
09:55AM	Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know (Zacks)
Feb-24-25 08:30AM	Mirums CTEXLI (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) (Business Wire)
07:31AM	Mirum drug for rare genetic disease gains FDA approval (BioPharma Dive)
Feb-19-25 04:04PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 (Business Wire)
Feb-10-25 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-24-25 12:00PM	Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-14-25 08:50AM	Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-13-25 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates (Business Wire) +6.49%
Jan-10-25 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-06-25 04:04PM	Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-24 11:30AM	Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? (Zacks)
Dec-10-24 06:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-06-24 06:46AM	Mirum Pharmaceuticals price target raised to $74 from $69 at JMP Securities (TipRanks)
Nov-14-24 08:00AM	Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLDs The Liver Meeting (Business Wire) +5.33%
Nov-13-24 02:09AM	Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Nov-12-24 09:15AM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Nov-08-24 06:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-24 04:30PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Nov-04-24 04:30PM	Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 (Business Wire)
Oct-31-24 10:02AM	Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know (Zacks)
08:30AM	Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Oct-23-24 08:49AM	Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth (Insider Monkey)
Oct-10-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:30AM	Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis (Business Wire)
Oct-09-24 05:18PM	Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ... (GuruFocus.com)
Sep-10-24 08:45PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 01:31PM	Four Biotech Stocks Rally Toward Buy Points As Funds Load Up (Investor's Business Daily)
11:31AM	Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue? (Zacks)
Aug-28-24 04:01PM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-19-24 11:06AM	Mirum (MIRM) Banks on Livmarli, Overdependence a Concern (Zacks)
Aug-09-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.79%
Aug-08-24 11:01AM	Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top (Zacks)
Aug-07-24 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-31-24 04:30PM	Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024 (Business Wire)
Jul-29-24 07:28AM	Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains? (Zacks)
Jul-25-24 08:30AM	Mirums LIVMARLI Now Approved for PFIC in Patients 12 Months and Older (Business Wire)
Jul-12-24 01:22PM	Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves (Investor's Business Daily)
Jul-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-09-24 10:37AM	Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion (Zacks)
Jul-08-24 11:38AM	Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why (Zacks)
08:30AM	Mirum Pharmaceuticals LIVMARLI Approved in the European Union for Patients with PFIC (Business Wire)
Jun-28-24 02:26PM	MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50 (Investor's Business Daily)
08:30AM	Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX (Business Wire)
Jun-25-24 11:31AM	Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling (Investor's Business Daily)
Jun-18-24 11:14AM	Mirum (MIRM) Soars on Interim Data From Liver Disease Studies (Zacks) -11.36%
05:46AM	Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock? (Zacks)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Brege Laura	Director	Sep 11 '25	Option Exercise	15.00	17,000	255,000	32,703	Sep 12 08:00 PM
Brege Laura	Director	Sep 11 '25	Sale	74.40	17,000	1,264,868	15,703	Sep 12 08:00 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Sep 12 '25	Sale	76.01	9,578	728,024	39,945	Sep 12 08:00 PM
LAURA BREGE	Director	Sep 11 '25	Proposed Sale	74.41	17,000	1,264,917		Sep 11 04:04 PM
Ramasastry Saira	Director	Sep 08 '25	Option Exercise	23.51	17,000	399,670	17,000	Sep 10 05:50 PM
SAIRA RAMASASTRY	Director	Sep 08 '25	Proposed Sale	77.04	17,000	1,309,716		Sep 08 04:06 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Aug 12 '25	Option Exercise	26.49	2,954	78,251	31,190	Aug 12 08:00 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 12 07:57 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 11 '25	Sale	62.00	40,000	2,480,000	138,641	Aug 12 07:57 PM
CHRISTOPHER PEETZ	Officer	Aug 11 '25	Proposed Sale	62.00	40,000	2,480,000		Aug 11 04:06 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Option Exercise	6.27	10,000	62,700	12,426	Aug 08 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Aug 07 '25	Sale	58.00	10,000	580,000	2,426	Aug 08 04:50 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Option Exercise	2.94	40,000	117,440	178,641	Aug 08 04:49 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Aug 07 '25	Sale	55.25	40,000	2,210,040	138,641	Aug 08 04:49 PM
JOLANDA MARIE HOWE	Officer	Aug 07 '25	Proposed Sale	58.00	10,000	580,000		Aug 07 04:26 PM
CHRISTOPHER PEETZ	Officer	Aug 07 '25	Proposed Sale	55.25	40,000	2,210,040		Aug 07 04:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 02 '25	Sale	48.25	564	27,213	2,903	Jul 03 06:48 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jul 03 '25	Sale	49.08	477	23,411	2,426	Jul 03 06:48 PM
JOLANDA MARIE HOWE	Officer	Jul 03 '25	Proposed Sale	49.08	477	23,411		Jul 03 01:13 PM
Fairey William	Director	Jun 11 '25	Sale	48.42	3,203	155,091	2,500	Jun 13 04:18 PM
WILLIAM C FAIREY	Director	Jun 11 '25	Proposed Sale	48.42	3,203	155,091		Jun 11 04:05 PM
Ramasastry Saira	Director	Jun 03 '25	Option Exercise	14.12	2,500	35,300	2,500	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 02 '25	Sale	46.20	5,703	263,492	0	Jun 04 04:11 PM
Ramasastry Saira	Director	Jun 03 '25	Sale	45.74	2,500	114,352	0	Jun 04 04:11 PM
SAIRA RAMASASTRY	Director	Jun 03 '25	Proposed Sale	45.74	2,500	114,352		Jun 03 05:07 PM
SAIRA RAMASASTRY	Director	Jun 02 '25	Proposed Sale	46.20	5,703	263,492		Jun 02 06:43 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 18 '25	Sale	44.45	2,415	107,343	2,426	Mar 19 05:40 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Option Exercise	2.94	52,900	155,526	59,547	Mar 18 09:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Mar 17 '25	Sale	44.35	57,606	2,554,763	4,841	Mar 18 09:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 17 '25	Sale	44.21	7,879	348,364	18,672	Mar 18 09:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 17 '25	Sale	44.21	27,279	1,206,122	138,641	Mar 18 09:30 PM
Heron Patrick J	Director	Mar 14 '25	Buy	44.11	528	23,291	168,651	Mar 18 05:04 PM
Heron Patrick J	Director	Mar 17 '25	Buy	43.93	21	923	168,672	Mar 18 05:04 PM
JOLANDA MARIE HOWE	Officer	Mar 18 '25	Proposed Sale	44.45	2,415	107,343		Mar 18 04:12 PM
JOLANDA MARIE HOWE	Officer	Mar 17 '25	Proposed Sale	44.36	54,706	2,426,540		Mar 17 04:21 PM
Heron Patrick J	Director	Mar 10 '25	Buy	42.97	1,335	57,363	167,160	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 11 '25	Buy	43.77	963	42,155	168,123	Mar 12 04:51 PM
Heron Patrick J	Director	Mar 06 '25	Buy	43.89	1,335	58,597	165,245	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 07 '25	Buy	43.21	580	25,064	165,825	Mar 10 05:12 PM
Heron Patrick J	Director	Mar 04 '25	Buy	45.57	1,335	60,830	163,643	Mar 06 05:30 PM
Heron Patrick J	Director	Mar 05 '25	Buy	44.55	267	11,894	163,910	Mar 06 05:30 PM
Radovich Peter	PRESIDENT AND COO	Mar 04 '25	Sale	45.58	14,850	676,928	12,111	Mar 05 04:28 PM
Radovich Peter	Officer	Mar 04 '25	Proposed Sale	45.52	14,850	675,956		Mar 04 04:43 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Option Exercise	2.94	40,000	117,440	155,920	Mar 04 04:26 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Mar 03 '25	Sale	46.91	40,000	1,876,353	115,920	Mar 04 04:26 PM
CHRISTOPHER PEETZ	Officer	Mar 03 '25	Proposed Sale	46.91	40,000	1,876,280		Mar 03 04:49 PM
Radovich Peter	PRESIDENT AND COO	Feb 03 '25	Sale	48.22	2,627	126,681	26,961	Feb 04 05:30 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 03 '25	Sale	48.22	9,102	438,921	115,920	Feb 04 05:30 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 03 '25	Sale	48.22	1,064	51,309	4,232	Feb 04 05:30 PM
Radovich Peter	PRESIDENT AND COO	Jan 24 '25	Sale	47.92	3,177	152,256	29,588	Jan 27 04:50 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 24 '25	Sale	47.92	902	43,228	3,524	Jan 27 04:48 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 24 '25	Sale	47.92	6,837	327,658	125,022	Jan 27 04:48 PM
Quan Joanne	CHIEF MEDICAL OFFICER	Jan 17 '25	Sale	45.86	6,969	319,598	5,649	Jan 21 04:21 PM
Radovich Peter	PRESIDENT AND COO	Jan 07 '25	Sale	42.82	1,998	85,545	27,015	Jan 08 04:44 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Jan 07 '25	Sale	42.82	7,489	320,644	119,359	Jan 08 04:42 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 07 '25	Sale	42.82	750	32,111	2,926	Jan 08 04:38 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Option Exercise	2.94	2,500	7,350	4,926	Nov 15 05:34 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Nov 14 '24	Sale	47.10	2,500	117,752	2,426	Nov 15 05:34 PM

MBX

MBX Biosciences Inc

ARQT

Arcutis Biotherapeutics Inc

MIRM

Mirum Pharmaceuticals Inc

Upgrade your FINVIZ experience